Strategic Partnership

RegAff wants to build strategic partnerships with Pharma and Biotech companies so that it can deliver more value and more cost effectively. Such partnerships would have a multi-year contract and would provide to companies:

• In a growth phase for a small to medium sized business, an increase in capability without a corresponding, fully allocated fixed cost increase
  
• Cost efficiency by enabling internal resource to be focused on growth through core business initiatives and using RegAff for routine activities
• Provide a full regulatory affairs service for a small Pharma or Biotech company thus avoiding fixed cost and resource issues.
• Achieve earlier ROI from Asia markets by earlier Marketing Approvals
  
• A way of delivering non-core but important business objectives
  
• Source of people to recruit

Benefits of Regulatory Partnerships

• Fixed costs become variable costs
• Ability to invest in in-house in highly skilled competencies
• Enables business growth strategies without risk of too many fixed costs
• Sustainable model of cost efficiency around routine activities
• Information management: leading edge without high fixed cost
• Leading (instead of following) corporate mandates about cost and headcount